Rectal Cancer Clinical Trial
— GRECCAR12Official title:
Optimisation of Response for Organ Preservation in Rectal Cancer : Neoadjuvant Chemotherapy and Radiochemotherapy vs. Radiochemotherapy
Verified date | March 2024 |
Source | University Hospital, Bordeaux |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Standard treatment of rectal cancer is rectal excision with neoadjuvant radiochemotherapy. A new concept suggests organ preservation as an alternative to rectal excision in good responders after neoadjuvant radiochemotherapy to decrease surgical morbidity and increase quality of life. The rational is the fact that 15% of patients have sterilized tumours after radiochemotherapy for T3T4 rectal cancer. The French GRECCAR 2 trial is the first phase III trial investigating this strategy: patients with T2T3 low rectal carcinomas (size ≤4 cm) received 50 Gy with capecitabine and good clinical responders (≤2 cm) were randomized between local and rectal excision. The main findings were: the rate of complete pathologic response was higher after radiochemotherapy for small T2T3 than for T3T4 tumours (40% vs 15% ypT0) and good pathologic responders (ypT0-1) were associated with zero positive mesorectal nodes. The objective of the new trial is to increase the proportion of patients treated with organ preservation by optimizing tumour response. As compared to Folfiri, tritherapy Folfirinox has been shown to enhance the response rate. In patients with colorectal metastases, response rate and R0 resection were twice higher, resulting in improved survival. Folfirinox also increases response and chance of R0 resection rates in initially unresectable colorectal metastases, compared to standard or intensified bi-chemotherapy regimens. Adding two months of neoadjuvant chemotherapy (Folfirinox) before radiochemotherapy, the investigators expect to increase chance of organ preservation rate, as compared to radiochemotherapy alone.
Status | Active, not recruiting |
Enrollment | 218 |
Est. completion date | June 2024 |
Est. primary completion date | June 9, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Rectal adenocarcinoma - cT2T3 - cN0-1 (= 3 positive lymph nodes or size =8mm) - Tumour size =4 cm - Location =10 cm from the anal verge - No distant metastasis - Patient =18 years - ECOG =2 - Effective contraception during the study - Patient and doctor have signed informed consent Exclusion Criteria: - T1 or T4 - Tumour size >4cm - N2 (>3 positive lymph nodes or size >8mm) - Tumour > 10 cm from the anal verge - Distant metastasis - Chronic intestinal inflammation and/or bowel obstruction - Contra indication for chemotherapy and/or radiotherapy - Previous pelvic radiotherapy or chemotherapy - Severe renal, hepatic insufficiency (serum creatinine<30ml/min) - Peripheral neuropathy > grade 1 - Complete or partial Dihydropyrimidine deshydrogenase (DPD) deficiency (uracilemia = 16 ng/mL) - Concomitant treatment with millepertuis, yellow fever vaccine, phenytoin or sorivudine (or chemically equivalent) - Pregnant or breast-feeding woman. - Persons deprived of liberty or under guardianship - Impossibility for compliance to follow-up |
Country | Name | City | State |
---|---|---|---|
France | Service de Chirurgie Digestive, CHU Amiens Picardie | Amiens | |
France | Service de Chirurgie Digestive, CHU de Besançon | Besançon | |
France | Service de Chirurgie Digestive, Hôpital Haut-Lévêque - CHU de Bordeaux | Bordeaux | |
France | Service de Chirurgie Digestive, Institut Bergonié | Bordeaux | |
France | Service de Chirurgie Digestive, CHU Estaing - CHRU Clermont Ferrand | Clermont-Ferrand | |
France | Service de Chirurgie Digestive, Hôpital Beaujon - APHP | Clichy | |
France | Service de Chirurgie Digestive, Centre Georges François Leclerc - Dijon | Dijon | |
France | Service de Chirurgie Digestive, Hôpital Albert Michallon - CHU de Grenoble | La Tronche | |
France | Service de Chirurgie Digestive, Centre Oscar Lambret - Lille | Lille | |
France | Service de Chirurgie Digestive, Centre Léon Bérard - Lyon | Lyon | |
France | Service de Chirurgie Digestive, Hôpital Lyon Sud - CHU Lyon | Lyon | |
France | Service de Chirurgie Digestive, CHU de la Timone - Marseille | Marseille | |
France | Service de Chirurgie Digestive, Institut Paoli Calmette - Marseille | Marseille | |
France | Service de Chirurgie Digestives, Hôpital Européen de Marseille | Marseille | |
France | Service de Chirurgie Digestive, Institut du Cancer de Montpellier | Montpellier | |
France | Service d'Oncologie et Radiothérapie, Centre Azuréen de Cancérologie | Mougins | |
France | Service de Chirurgie Digestive,Institut de Cancérologie de Lorraine | Nancy | |
France | Service de Chirurgie Digestive, Hôtel Dieu - CHU de Nantes | Nantes | |
France | Service de Chirurgie Digestive, CHU Carémeau - Nîmes | Nîmes | |
France | GH Paris Saint Joseph | Paris | |
France | Service de Chirurgie Digestive et Oncologique, Hôpital Bicêtre - APHP | Paris | |
France | Service de Chirurgie Digestive, Hôpital les Diaconnesses | Paris | |
France | Service de Chirurgie Digestive, Hôpital Saint-Antoine - APHP | Paris | |
France | Service de Chirurgie Digestive, Hôpital Saint-Louis - APHP Paris | Paris | |
France | Service de Chirurgie Digestive, Hôpital Pontchaillou - CHU Rennes | Rennes | |
France | Service de Chirurgie Digestive, Hôpital Charles Nicolle - CHU de Rouen | Rouen | |
France | Service de Chirurgie Digestive, Hôpital Purpan - CHU de Toulouse | Toulouse | |
France | Service de chirurgie digestive, CHRU de Nancy -Hôpital de Brabois | Vandœuvre-lès-Nancy | |
France | Département de chirurgie digestive, Institut Gustave Roussy | Villejuif |
Lead Sponsor | Collaborator |
---|---|
University Hospital, Bordeaux |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Rate of organ preservation and absence of stoma | Number of patients with organ preservation and absence of stoma at 1 year after surgery | 1 year after surgery | |
Secondary | Compliance to treatment | Number of patients receiving full neoadjuvent treatment and the allocated surgery | From beginning of neoadjuvant treatment until surgery, expected average 20 weeks after neoadjuvant treatment | |
Secondary | Tolerance to treatment | Number of patients with adverse events | From beginning of neoadjuvant treatment until 1 year after surgery | |
Secondary | Rate of clinical complete response | To determine the rate of grade 1 : no tumor at digital examination | At 8 weeks after neoadjuvant treatment | |
Secondary | Rate of radiological response | To determine the rate of tumor = 2 cm with TRG1-3 at MRI | At 8 weeks after neoadjuvant treatment | |
Secondary | Rate of complete pathologic response | To determine the rate of ypT0 | At surgery, expected average 10 weeks after neoadjuvant treatment | |
Secondary | Correlation between radiological and clinical response | To analyse the correlation between radiological response ( tumor = 2 cm with TRG1-3 at MRI) and clinical response (grade 1) | Between 8 to 10 weeks after neoadjuvant treatment | |
Secondary | Correlation between radiological (radiomic analysis) and pathologic response | To analyse the correlation between radiological response ( tumor = 2 cm with TRG1-3 at MRI) and pathological response (ypT0) | Between 8 to 10 weeks after neoadjuvant treatment | |
Secondary | Rate of curative surgery | To determine the rate of R0 resection | At surgery, expected average 10 weeks after neoadjuvant treatment | |
Secondary | Surgical morbidity | To analyse the cumulative Clavien-Dindo at 1 year | From surgery until 1 year of follow-up | |
Secondary | Quality of life | To examine score of questionnaires : QLQ CR-30, QLQ CR-29 | From randomization until 1 year after surgery | |
Secondary | Local recurrence | To determine the rate of local recurrence at 3 years | From surgery until 3 years of follow-up | |
Secondary | Overall survival | To determine the rate of overall survival at 3 years | From surgery until 3 years of follow-up | |
Secondary | Disease-free survival | To determine the rate of disease-free survival at 3 years | From surgery until 3 years of follow-up |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06380101 -
Evaluating a Nonessential Amino Acid Restriction (NEAAR) Medical Food With Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer (LARC)
|
N/A | |
Active, not recruiting |
NCT05551052 -
CRC Detection Reliable Assessment With Blood
|
||
Recruiting |
NCT04323722 -
Impact of Bladder Depletion on Mesorectal Movements During Radiotherapy in Rectal Cancer
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04088955 -
A Digimed Oncology PharmacoTherapy Registry
|
||
Active, not recruiting |
NCT01347697 -
Collagen Implant (Biological Mesh) Versus GM Flap for Reconstruction of Pelvic Floor After ELAPE in Rectal Cancer
|
N/A | |
Recruiting |
NCT04495088 -
Preoperative FOLFOX Versus Postoperative Risk-adapted Chemotherapy in Patients With Locally Advanced Rectal Cancer
|
Phase 3 | |
Withdrawn |
NCT03007771 -
Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia
|
Phase 1 | |
Terminated |
NCT01347645 -
Irinotecan Plus E7820 Versus FOLFIRI in Second-Line Therapy in Patients With Locally Advanced or Metastatic Colon or Rectal Cancer
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT03520088 -
PROSPECTIVE CONTROLLED AND RANDOMIZED STUDY OF THE GENITOURINARY FUNCTION AFTER RECTAL CANCER SURGERY IN RELATION TO THE DISSECTION OF THE INFERIOR MESENTERIC VESSELS
|
N/A | |
Recruiting |
NCT05556473 -
F-Tryptophan PET/CT in Human Cancers
|
Phase 1 | |
Recruiting |
NCT04749381 -
The Role of TCM on ERAS of Rectal Cancer Patients
|
Phase 2 | |
Enrolling by invitation |
NCT05028192 -
Mitochondria Preservation by Exercise Training: a Targeted Therapy for Cancer and Chemotherapy-induced Cachexia
|
||
Recruiting |
NCT03283540 -
Transanal Total Mesorectal Excision for Rectal Cancer on Anal Physiology + Fecal Incontinence
|
||
Completed |
NCT04534309 -
Behavioral Weight Loss Program for Cancer Survivors in Maryland
|
N/A | |
Recruiting |
NCT05914766 -
An Informational and Supportive Care Intervention for Patients With Locally Advanced Rectal Cancer
|
N/A | |
Recruiting |
NCT04852653 -
A Prospective Feasibility Study Evaluating Extracellular Vesicles Obtained by Liquid Biopsy for Neoadjuvant Treatment Response Assessment in Rectal Cancer
|
||
Recruiting |
NCT03190941 -
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
|
Phase 1/Phase 2 | |
Completed |
NCT02810652 -
Perioperative Geriatrics Intervention for Older Cancer Patients Undergoing Surgical Resection
|
N/A | |
Terminated |
NCT02933944 -
Exploratory Study of TG02-treatment as Monotherapy or in Combination With Pembrolizumab to Assess Safety and Immune Activation in Patients With Locally Advanced Primary and Recurrent Oncogenic RAS Exon 2 Mutant Colorectal Cancer
|
Phase 1 |